

BCCA Protocol Summary for Recurrent/Metastatic Salivary Gland cancers of the Head and Neck with Tamoxifen

Protocol Code *HNSAVTAM*

Tumour Group *Head and Neck*

Contact Physician *Dr. Cheryl Ho*

ELIGIBILITY:

- ER positive or negative status
- Recurrent malignancy for whom resection, radiotherapy or chemotherapy are no longer treatment options
- Current evidence based on case studies

TESTS:

- Histologically confirmed recurrence of a salivary gland carcinoma

TREATMENT:

Drug	Dose	BCCA Administration Guideline
Tamoxifen	20 mg PO once daily	PO

- DISCONTINUE drug for severe side effects OR obvious progression of disease

PRECAUTIONS:

1. **Women:** hot flushes, vaginitis.
2. **Men:** decrease in libido, hot flushes.
3. **Thromboembolism:** Tamoxifen is associated with an increased risk of thromboembolism that is comparable to estrogen replacement therapy.

Contact Dr. Cheryl Ho or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date Activated 1 Feb 2012

Date(s) Revised

REFERENCE

1. Elkin AD, Jacobs CD. Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. *J Cancer Res Clin Oncol* 2008;134:1151-3.
2. Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. *J Laryngol Otol* 1997; 111:1186-89.